Compared with an overall response rate (ORR) of 55% in non-small-cell lung cancer (clinical trial KEYNOTE-021)51, an anti-PD-L1 therapy only received an ORR of 11.2% in GC (clinical trial KEYNOTE-059)52. This evidence concerns the gene CD274 and non-small cell lung carcinoma.